GenMark Diagnostics Receives FDA Clearance for ePlex BCID Gram-Positive Panel

Dec 20, 2018

|

NEW YORK (GenomeWeb) – GenMark Diagnostics said today that it has received US Food and Drug Administration 510(k) clearance for its ePlex Blood Culture Identification Gram-Positive (BCID-GP) Panel.

The firm had announced toward the end of June that it applied to the FDA for market clearance.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

GenMark Diagnostics Receives FDA Clearance for ePlex BCID Gram-Positive Panel

To read the full story....

Breaking News

OraSure Technologies Q4 Revenues Rise 27 Percent, Beat Analysts' Estimate

CMS Releases New Guidance Requiring Payors to Cover COVID-19 Testing Without Cost Sharing

UPDATED: Quidel At-Home, Rapid Antigen, COVID-19 Test Gets FDA Emergency Use Authorization

FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

OpGen Unyvero IVD Platform Nabs Chinese Regulatory Approval

Featured White Papers

What's Popular?

Roche SARS-CoV-2 Antigen Test Nabs German Approval for At-Home Self-Testing

Mistakes Were Made in Regulation of SARS-CoV-2 Serology Tests, FDA Officials Acknowledge

FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

Mobidiag SARS-CoV-2, Influenza A/B, RSV Test Receives CE Mark

Sponsorships